歌礼制药(01672.HK) 公布，低剂量ASC47与司美格鲁肽联合用药的临床前数据、澳洲Ib期ASC47单药研究的安全性、耐受性以及初步疗效，ASC47与司美格鲁肽联合治疗肥胖症的美国新药临床试验(IND)申请，近期获得美国食品药品监督管理局(FDA)批准，预计将于今年第二季度末完成首例患者给药。
公告披露，ASC47是一款脂肪靶向、治疗肥胖症的减重不减肌的候选药物。(js/w)
(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.